StreetAlpha.app
Home › Stocks › TECX

Tectonic Therapeutic, Inc. (TECX)

Healthcare
$20.73
▼ −1.47%
LAST CLOSE · NOV 20

Tectonic Therapeutic develops protein and antibody drugs that act on G protein coupled receptors, led by a candidate for pulmonary hypertension. It last closed at $20.73 on Nov 20, down 1.47% on the day. The next earnings report for TECX is expected around Thu, Feb 4, 2027, after the close. For the quarter ended Sep 2026, TECX reported EPS of -$1.08. Over its last 8 reports the stock moved an average of 3.7% the session after earnings. Over the last 12 months TECX insiders bought $182K of stock on the open market and sold $651K, according to SEC Form 4 filings.

AI Auto Pilots
Is TECX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold TECX.

Key Stats

Last 12 months
Results
Net income
−$88.1M
EPS (diluted)
−$4.63
Free cash flow
−$69.3M
Valuation
Market cap
$413.5M
19.9M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$234.7M
At Sep 30
Shareholder equity
$229.3M
Shares outstanding
19.9M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$119.1M−$119.1MFY2021FY2022: −$105.9M−$105.9MFY2022FY2023: −$42.8M−$42.8MFY2023FY2024: −$58.0M−$58.0MFY2024FY2025: −$74.2M−$74.2MFY2025

From TECX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 4
Estimated date · After the close
Reported EPS
-$1.08
Quarter ended Sep 2026
Year ago EPS
-$1.02
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.33Dec '24Mar 2025: -$0.93Mar '25Jun 2025: -$1.07Jun '25Sep 2025: -$1.02Sep '25Dec 2025: -$1.03Dec '25Mar 2026: -$1.34Mar '26Jun 2026: -$1.18Jun '26Sep 2026: -$1.08Sep '26Latest -$1.08
Revenue by quarter
Not enough quarters on file yet.
How TECX moved after its last 8 reports
Average move the session after a report ±3.7%
Aug 6, 2026After the close+2.5%
May 7, 2026After the close+7.9%
Feb 26, 2026After the close−2.0%
Nov 6, 2025After the close+1.7%
Aug 7, 2025After the close+1.8%
May 8, 2025After the close−6.0%
Mar 20, 2025After the close−4.6%
Nov 7, 2024After the close−3.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on TECXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on TECX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on TECX

Technical Analysis

TECX · as of the Nov 20 close · updated each morning
Downtrend

The stock sits between its 20 and 50 day averages. It is 36% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 46). The nearest support is the 20 day average at $20.57, and the nearest resistance the Pivot at $20.90.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 6.1%/day
Key levels
$39.5352 week high+90.7%
$28.10200 day average+35.6%
$27.56100 day average+32.9%
$22.4050 day average+8.1%
$21.44Swing high (Oct 29)+3.4%
$21.40Pivot R1+3.2%
$20.90Pivot+0.8%
$20.73Last close
$20.5720 day average−0.8%
$20.45Swing low (Oct 19)−1.4%
$20.24Pivot S1−2.4%
$16.7752 week low−19.1%
Indicators
RSI (14)45.70Middle of its rangeNeutral
MACD-0.41Above its signal lineBullish
Stochastic55.4Middle of its rangeNeutral
ADX (14)27.5Trending down
Williams %R-51.2Oversold below −80, overbought above −20Neutral
CCI (20)37.5Oversold below −100, overbought above 100Neutral
Rate of change+0.4%Change over 10 sessionsBullish
ATR (14)$1.27Typical daily range, 6.2% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for TECX

What happened before

See how TECX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow TECX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How TECX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for TECXHow many large options trades hit TECX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

TECX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲60 buying vs 49 selling
  • ▲Held by funds +1.7 pts
  • ▼Funds holding -7
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding116123−5.7%
In funds' top 10110.0%
Held by funds71.8%70.0%+1.7 pts
New / increased13 / 4725 / 39−6.3%
Reduced / sold out29 / 2040 / 11−3.9%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TECX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

TECX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$182K2 buys · 2 insiders
Sold$651K9 sales · 2 insiders
100% of the selling was under pre-arranged trading plans.
Cluster buy: 2 insiders bought $182K between Feb 10 and Feb 11.
2026-02 bought $182K2026-03 sold $567K2026-04 sold $31K2026-05 sold $32K2026-06 sold $6K2026-08 sold $3K2026-09 sold $12KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 30Peter McNamaraChief Scientific OfficerSale plan536$23.04$12K
Aug 25Peter McNamaraChief Scientific OfficerSale plan43$36.52$2K
Aug 12Peter McNamaraChief Scientific OfficerSale plan43$35.00$2K
Jun 30Peter McNamaraChief Scientific OfficerSale plan172$35.00$6K
May 4Marcella K. RuddyChief Medical OfficerSale plan1,065$30.00$32K
Apr 1Marcella K. RuddyChief Medical OfficerSale plan1,000$31.05$31K
Every insider buy and sale for TECX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See TECX insider trades →

From SEC Form 4 filings by TECX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TECX is in one of them and how their past TECX trades turned out.

TECX in the AI portfolios
Loading…

TECX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TECX in an article yet. Here's the latest on the wider market.

TECX in the news

About Tectonic Therapeutic

Tectonic Therapeutic is a biotechnology company based in Watertown, Massachusetts. It develops therapeutic proteins and antibodies that act on G protein coupled receptors, a family of cell surface molecules that help control many body functions. Its lead candidate, TX45, is a relaxin based molecule being tested for pulmonary hypertension linked to heart and lung disease. The company's work is aimed at patients with serious conditions where treatment options are limited.

Headquarters
Watertown, MA